Label: BORTEZOMIB injection, powder, lyophilized, for solution

  • NDC Code(s): 70771-1708-1
  • Packager: Zydus Lifesciences Limited
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated May 5, 2022

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC 70771-1708-1

    Bortezomib for Injection

    3.5 mg/vial

    For Intravenous or Subcutaneous Use

    One Single-dose Vial

    Rx only

    vial label

    NDC 70771-1708-1

    Bortezomib for Injection – Carton label

    3.5 mg/vial

    For Intravenous or Subcutaneous Use

    Reconstitution Information

    SUBCUTANEOUS INJECTION ONLY

    0.9% NaCl

    Add

    1.4 mL

    0.9% Sodium Chloride

    To make

    2.5 mg/mL

    final concentration

    INTRAVENOUS INJECTION ONLY

    0.9% NaCl

    Add

    3.5 mL

    0.9% Sodium Chloride

    To make

    1 mg/mL

    final concentration

    One Single-dose Vial

    Rx only

    carton label

    Reconstitution Information – Inside Flap (All cartons)

    SUBCUTANEOUS INJECTION ONLY

    0.9% NaCl

    Add

    1.4 mL

    0.9% Sodium Chloride

    To make

    2.5 mg/mL

    final concentration

    INTRAVENOUS INJECTION ONLY

    0.9% NaCl

    Add

    3.5 mL

    0.9% Sodium Chloride

    To make

    1 mg/mL

    final concentration

    Inside Flap image
  • INGREDIENTS AND APPEARANCE
    BORTEZOMIB 
    bortezomib injection, powder, lyophilized, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:70771-1708
    Route of AdministrationINTRAVENOUS, SUBCUTANEOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    BORTEZOMIB (UNII: 69G8BD63PP) (BORTEZOMIB - UNII:69G8BD63PP) BORTEZOMIB1 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    MANNITOL (UNII: 3OWL53L36A)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:70771-1708-11 in 1 CARTON05/02/2022
    13.5 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21020405/02/2022
    Labeler - Zydus Lifesciences Limited (918596198)
    Establishment
    NameAddressID/FEIBusiness Operations
    Zydus Hospira Oncology Private Limited676190889ANALYSIS(70771-1708) , LABEL(70771-1708) , MANUFACTURE(70771-1708) , PACK(70771-1708)